Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH-HOME: Functionality and Performance Study of Accessorized Prefilled Syringe and Autoinjector for Subcutaneous Tezepelumab in Severe Asthma
2018-004588-30Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tezepelumab in severe asthma and asthma (2 arms), sponsored by AstraZeneca. Started Apr 2019; status: completed.
02
Drugs
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on 2018-004588-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004588-30.